Interim Analysis

The timing, methodology, and decision rules must be fully documented before the first patient is enrolled. This eliminates data-driven opportunism.

• Timing: Defined by calendar time or information fraction (e.g., at 50% of expected events).
• Boundaries: Stopping rules using O'Brien-Fleming or Pocock boundaries are pre-defined.
• Alpha Spending: The exact amount of Type I error allocated to each look is fixed.

Repeatedly testing accumulating data inflates the Type I error rate. Alpha spending functions mathematically allocate the overall significance level across multiple looks.

• O'Brien-Fleming: Conservative early on; requires extreme results to stop early.
• Pocock: Uses a constant nominal p-value at each look.
• Lan-DeMets: A flexible approach that approximates discrete boundaries without requiring the exact number of looks to be fixed in advance.

To maintain operational integrity and blinding, the analysis is performed by an external, independent committee, not the sponsor or investigators.

• Firewall: The IDMC reviews unblinded data and makes recommendations without revealing results to the trial team.
• Charter: Governed by a strict charter defining membership, meeting frequency, and decision-making authority.
• Recommendations: The IDMC can recommend continuing, modifying, or stopping the trial.

Pre-defined thresholds on the test statistic determine whether to stop for efficacy or futility.

• Efficacy Boundary: If the observed treatment effect crosses this upper threshold, the trial stops early for overwhelming benefit.
• Futility Boundary: If the effect falls below a lower threshold, the trial stops because the probability of a positive final result is negligible.
• Conditional Power: Often used for futility; calculates the probability of final success given current data and assumed future trends.

Knowledge of interim results can alter investigator behavior and patient enrollment, introducing operational bias. Strict procedures prevent this.

• Blind Maintenance: The sponsor and clinical team remain fully blinded to treatment assignments.
• No Investigative Site Access: Interim results are never shared with individual clinical sites.
• Minimal Data Freeze: A targeted data lock is performed only for the specific endpoints required by the IDMC.

For a pivotal trial intended for FDA or EMA submission, the interim analysis plan must be reviewed by regulators.

• Type I Error Control: Regulators require strong control of the family-wise error rate.
• Special Protocol Assessment (SPA): In the US, the FDA may formally agree to the interim analysis plan in advance.
• Confirmatory Evidence: A trial stopped early for efficacy may still require a second confirmatory trial if the sample size is small.

The false positive risk—concluding a diagnostic AI is effective when it is not. In interim analyses, each peek at the data inflates this error rate. Alpha spending functions (e.g., O'Brien-Fleming, Pocock) allocate the overall significance level across multiple looks.

• O'Brien-Fleming boundaries: Very conservative early, easing later
• Lan-DeMets approach: Flexible spending without pre-fixed look timing
• Critical for maintaining regulatory credibility with the FDA

A pre-specified rule allowing a trial to stop early when conditional power—the probability of eventual success given current data—falls below a threshold. This prevents wasting patient resources and investigator effort on a diagnostic tool unlikely to demonstrate efficacy.

• Non-binding futility: IDMC may recommend but sponsor decides
• Binding futility: Mandatory stop; inflates Type II error if ignored
• Often set at conditional power < 10-20%

A multi-disciplinary panel of clinicians, biostatisticians, and ethicists independent of the sponsor. The IDMC is the sole body reviewing unblinded interim results to protect study integrity and patient safety.

• Operates under a formal charter defining stopping rules
• Recommends continue, modify, or terminate
• Prevents sponsor bias from influencing ongoing trial conduct

The probability that the final study result will be statistically significant, given the observed data at interim and an assumed effect for the remaining data. A key metric for futility assessments.

• Optimistic conditional power: Assumes original design effect size
• Conservative conditional power: Assumes effect under the null hypothesis
• Values below 20% commonly trigger futility discussions

A class of trial designs where data are analyzed at pre-specified intervals after groups of subjects complete follow-up. Each analysis tests the same hypothesis with an adjusted significance level to maintain overall family-wise error rate.

• Contrasts with fully sequential designs (after every observation)
• Pocock boundaries: Equal nominal significance at each look
• O'Brien-Fleming boundaries: Very stringent early, near-final alpha at end